Entity Central Index Key Document Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash And Cash Equivalents At Carrying Value Prepaid expenses Prepaid Expense Current Total current assets Assets Current Equipment, net Property Plant And Equipment Net In-process research and development Intangible Assets Net Excluding Goodwill Goodwill Goodwill Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities Liabilities Current [Abstract] Notes payable - current portion Notes Payable Current Accounts payable Accounts Payable Current Accrued expenses and other current liabilities Accounts Payable And Accrued Liabilities Current Accrued collaborative expenses Other Accrued Liabilities Current Total current liabilities Liabilities Current Notes payable - noncurrent Long Term Notes Payable Deferred taxes Deferred Tax Liabilities Noncurrent Other noncurrent liabilities Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies Commitments And Contingencies Stockholders’ equity Stockholders Equity [Abstract] Preferred stock; $.0001 par value; 100,000,000 shares authorized; none issued or outstanding as of March 31, 2015 and December 31, 2014, respectively Preferred Stock Value Common stock; $.0001 par value; 125,000,000 shares authorized; 24,721,143 and 18,439,482 shares issued and outstanding as of March 31, 2015 and December 31, 2014, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Preferred stock, par value (in dollars per share) Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value (in dollars per share) Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Expenses Operating Expenses [Abstract] Research and development Research And Development Expense General and administrative General And Administrative Expense Total expenses Operating Expenses Loss from operations Operating Income Loss Foreign exchange gains (losses) Foreign Currency Transaction Gain Loss Before Tax Interest (expense) income Interest Income Expense Net Net loss Net Income Loss Available To Common Stockholders Basic Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted average shares outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Equity impact of the value of new stock issued during the period in a private placement, net issuance cost. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Private Placement Private Placement [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Issuance of common stock and warrants pursuant to a private placement, net of issuance costs of $2,473,189 Stock Issued In Private Placement Net Value Issuance of common stock and warrants pursuant to a private placement, net of issuance costs of $2,473,189 (in shares) Stock Issued During Period Shares New Issues Issuance of warrant pursuant to loan agreement Adjustments To Additional Paid In Capital Warrant Issued Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Net loss Balances Balance (in shares) Issuance costs. Issuance cost Issuance Costs Cost paid in connection with private placement. Incurred but unpaid private/public placement costs. The amount of deferred tax liability that the Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. The amount of goodwill that the Entity acquires in a noncash (or part noncash) acquisition. Represents the amount associated with the acquisition of a business when the cash held by the acquired business exceeds the cash payments to acquire the business. Incurred but unpaid public offering costs. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Amortization of debt discount recorded as interest expense Amortization Of Debt Discount Premium Stock-based compensation expense Share Based Compensation Unrealized foreign exchange gain Foreign Currency Transaction Gain Loss Unrealized Change in fair value of derivative Unrealized Gain Loss On Derivatives Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Prepaid expenses Increase Decrease In Prepaid Expense Accounts payable Increase Decrease In Accounts Payable Accrued expenses and other current liabilities Increase Decrease In Accrued Liabilities Other Accrued Liabilities, collaborative expenses Increase Decrease In Other Accrued Liabilities Other noncurrent liabilities Increase Decrease In Other Noncurrent Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Cash acquired in business combination Cash Acquired From Acquisition Restricted cash Increase Decrease In Restricted Cash Net cash provided by investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Proceeds from loans Proceeds From Short Term Debt Costs paid in connection with loans Repayments Of Short Term Debt Proceeds from sales of common stock in private placement Proceeds From Issuance Of Private Placement Costs paid in connection with private placement Costs Paid In Connection With Private Placement Public offering costs paid Payments Of Stock Issuance Costs Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net increase in cash and cash equivalents Net Cash Provided By Used In Continuing Operations Cash and cash equivalents Cash And Cash Equivalents At Carrying Value [Abstract] Beginning of period End of period Cash paid for interest Interest Paid Incurred but unpaid private/public placement costs Incurred But Unpaid Private Public Placement Costs Supplemental disclosure of noncash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Common stock issued as consideration for business acquisition Stock Issued1 Plus liabilities assumed: Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed [Abstract] Accrued expenses and other Noncash Or Part Noncash Acquisition Payables Assumed1 ProteoSys milestone payable Noncash Or Part Noncash Acquisition Other Liabilities Assumed1 Deferred tax liability Noncash Or Part Noncash Acquisition Deferred Tax Liability Assumed Less assets acquired: Noncash Or Part Noncash Acquisition Value Of Assets Acquired [Abstract] Prepaid expenses Noncash Or Part Noncash Acquisition Other Assets Acquired1 Equipment Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 In-process research and development Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 Goodwill Noncash Or Part Noncash Acquisition Goodwill Acquired Cash acquired in business merger Cash Acquired In Business Merger Incurred but unpaid public offering costs Incurred But Unpaid Public Offering Costs NATURE OF OPERATIONS AND LIQUIDITY Nature of Operations and Liquidity Nature Of Operations Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Business Combinations [Abstract] Business Acquisition Business Combination Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss Per Share of Common Stock Earnings Per Share [Text Block] The entire disclosure for a license agreement between one or more parties. LICENSE AGREEMENT License Agreements License Agreement Disclosure [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Co Development And License Agreement Disclosure [Abstract] Co-Development and License Agreement Collaborative Arrangement Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock Option Plan Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments Commitments And Contingencies Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Basis Of Accounting Policy Policy [Text Block] Consolidation Consolidation Policy [Text Block] Disclosure of accounting policy for significant risks and uncertainties. Significant Risks and Uncertainties Significant Risks And Uncertainties Policy [Text Block] Use of Estimates Use Of Estimates Research and Development Costs Research And Development Expense Policy Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Loss Per Share Earnings Per Share Policy [Text Block] Business Combinations Business Combinations Policy Goodwill Goodwill And Intangible Assets Goodwill Policy Recent Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule Of Business Acquisitions By Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] Represents information pertaining to Mind-NRG. Mind-NRG Mind N R G [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Aggregate Consideration Allocated to Assets Acquired and Liabilities Assumed Based On Estimated Fair Value Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block] Schedule of Accrued Expenses and Other Liabilities Schedule Of Accrued Liabilities Table [Text Block] Computation of Basic and Diluted Loss Per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Securities Excluded from Calculation of Weighted Average Shares Outstanding as their Effect is Antidilutive Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Term A Loans and Debt Discount Schedule Of Debt Table [Text Block] Expected Repayment of Term A loan principal Schedule Of Maturities Of Long Term Debt Table [Text Block] Schedule of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] STOCK OPTION PLAN Summary of Assumptions Used in Black Scholes Model to Estimate Fair Value of Stock Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Nature Of Operations And Liquidity Disclosure [Abstract] Disclosure pertaining to nature of operations and liquidity. Nature Of Operations And Liquidity [Table] Nature Of Operations And Liquidity [Table] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Represents information pertaining to Mitsubishi Tanabe Pharma Corporation ("Mitsubishi"). Mitsubishi Mitsubishi Tanabe Pharma Corporation [Member] Type of Arrangement and Non-arrangement Transactions Type Of Arrangement [Axis] Arrangements and Non-arrangement Transactions Arrangements And Nonarrangement Transactions [Member] Co-development and License Agreement Collaborative Arrangement [Member] Products and Services Product Or Service [Axis] Products and Services Products And Services [Domain] Represents information pertaining to MIN-202. MIN-202 M I N202 [Member] Major Types of Debt and Equity Securities Major Types Of Debt And Equity Securities [Axis] Major Types of Debt and Equity Securities Major Types Of Debt And Equity Securities [Domain] Loan and security agreement. Loan and Security Agreement Loan And Security Agreement [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Term Loan Notes Payable To Banks [Member] Nature Of Operations And Liquidity [Line Items] Nature Of Operations And Liquidity [Line Items] Share capital acquired (as a percent) Business Acquisition Percentage Of Voting Interests Acquired Payment of license fee License Costs Sale of stock consideration received on transaction after deduction of underwriting discount and issuance cost. Amount drew dawn during period Proceeds From Issuance Of Long Term Debt Shares of common stock issued Shares of common stock to purchase by warrant Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net proceeds from sale of common stock, net of underwriting discount Sale Of Stock Consideration Received On Transaction After Deduction Of Underwriting Discount And Issuance Cost Significant accounting policies. Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Finite-Lived Intangible Assets by Major Class Finite Lived Intangible Assets By Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name Finite Lived Intangible Assets Major Class Name [Domain] In-Process Research and Development In Process Research And Development [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Asset impairment charges Asset Impairment Charges Impairment of goodwill Goodwill Impairment Loss Number of shares of common stock Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued Aggregate consideration Business Combination Consideration Transferred Equity Interests Issued And Issuable Estimated fair value (in dollars per share) Business Acquisition Share Price Represents information relating to ProteoSys AG. ProteoSys Proteo Sys A G [Member] Assets acquired and liabilities assumed based on estimated fair values Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net [Abstract] Cash Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents Other assets Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other In-process research and development Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Indefinite Lived Intangible Assets Deferred tax liability Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Deferred Tax Liabilities Noncurrent Accrued expenses Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable Milestone payable Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other Total Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net (Increase) decrease in goodwill from reduction in deferred tax liability Goodwill Subsequent Recognition Of Deferred Tax Asset Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable for research and development costs. It is used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer). Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable for research funding. It is used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer). Accrued bonus Accrued Bonuses Current Research and development costs Accrued Research And Development Costs Current Accrued severance Accrued Employee Benefits Current Professional fees Accrued Professional Fees Current Primomed research funding Accrued Research Funding Current Interest payable Interest Payable Current Accrued excise and franchise taxes Accrual For Taxes Other Than Income Taxes Current Vacation pay Accrued Vacation Current Deferred rent, current Deferred Rent Credit Current Accrued expenses and other liabilities Weighted average shares of common stock outstanding Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Stock Issued Subject to Recourse Notes Convertible Debt Securities [Member] Common Stock Options Stock Option [Member] Warrants Warrant [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Securities outstanding excluded from the calculation of weighted average shares outstanding Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Represents the amount of potential milestone payments that will be made upon the achievement of certain milestones under the agreement. License Agreement Disclosure [Abstract] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Represents information pertaining to the license agreement entered into by the entity. License Agreement License Agreement [Member] Represents information pertaining to MIN-101. MIN-101 M I N101 [Member] Additional Products Product [Member] Range Range [Axis] Range Range [Member] Maximum Maximum [Member] Represents information pertaining to MIN-117. MIN-117 M I N117 [Member] License Agreement Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Potential milestone payments upon achievement of milestone Potential Milestone Payments Upon Achievement Of Milestone Represents the number of development milestones required under the agreement. Number of development milestones required Number Of Development Milestone Achievement Required Represents the term of extension of the collaborative agreement. Represents the potential payment to extend the term of the license agreement. Term of extension of the agreement Collaborative Arrangement Extension Term Potential extension payment License Extension Potential Payment Number of tranches. Debt Instrument [Table] Debt Instrument [Table] Credit Facility Credit Facility [Axis] Credit Facility Credit Facility [Domain] Term A loans. Term A Loans Term A Loans [Member] Term B loans. Term B Loans Term B Loans [Member] Scenario Statement Scenario [Axis] Scenario, Unspecified Scenario Unspecified [Domain] Scenario, Forecast Scenario Forecast [Member] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Axis] Debt Instrument, Redemption, Period Debt Instrument Redemption Period [Domain] 24 months Debt Instrument Redemption Period One [Member] Between 24 and 36 months Debt Instrument Redemption Period Two [Member] Prepaid Thereafter Debt Instrument Redemption Period Three [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Mind-NRG, SA. Mind-NRG, SA Mind N R G S A [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Aggregate principal amount Line Of Credit Facility Maximum Borrowing Capacity Number of tranches Number Of Tranches Interest rate (as a percent) Debt Instrument Interest Rate Stated Percentage Term loan, interest rate term Debt Instrument Interest Rate Terms Minimum percentage of interest rate on loan Debt Instrument Interest Rate Stated Percentage Rate Range Minimum Line of credit facility fee. Debt instrument final payments as percentage of total amount borrowed. Debt instrument final payment as percentage of total amount borrowed upon extended interest only period. Facility fee payment Line Of Credit Facility Fee Final payment of term loan Debt Instrument Final Payments As Percentage Of Amount Borrowed Extended interest of term loan Debt Instrument Final Payment As Percentage Of Amount Borrowed Upon Extended Interest Only Period Term A Loans Debt Instrument Carrying Amount Less: debt discount and financing costs Debt Instrument Unamortized Discount Less: current portion Long Term Debt Current Long-term portion Long Term Debt Noncurrent Interest expense Interest Expense Debt discount Number of installments. Minimum capital requirement for extension of interest only period. Sale of equity securities requirement for extension of interest only period. Debt instrument extended interest only period. Debt instrument reduced repayment period. Maximum period for prepayment of loans outstanding. Debt instrument prepayment fee percent. Number of installments period Number Of Installments Minimum capital requirement Minimum Capital Requirement For Extension Of Interest Only Period Sale of equity securities Sale Of Equity Securities Requirement For Extension Of Interest Only Period Extended interest period for debt instrument Debt Instrument Extended Interest Only Period1 Reduced repayment period for debt instrument Debt Instrument Reduced Repayment Period Term loans maturity date Debt Instrument Maturity Date Advance notice period to the lenders Maximum Period For Prepayment Of Loans Outstanding Term loan prepayment fee terms Debt Instrument Payment Terms Proportion of prepayment fees on outstanding balance Debt Instrument Prepayment Fee Percent 2015 Long Term Debt Maturities Repayments Of Principal In Next Twelve Months 2016 Long Term Debt Maturities Repayments Of Principal In Year Two 2017 Long Term Debt Maturities Repayments Of Principal In Year Three 2018 Long Term Debt Maturities Repayments Of Principal In Year Four Total Term A Loans Ownership interest percentage in an Investment that is pledged. Percentage of equity interests Equity Interest Percentage Pledged Percentage of company common stock issuable upon warrant exercises. Common stock exercise price per share. Expiration anniversary date of issuance. Aggregate number of shares of Common Stock issuable Percentage Of Company Common Stock Issuable Upon Warrant Exercises Consecutive trading days Debt Instrument Convertible Threshold Consecutive Trading Days Common stock exercise price per share Common Stock Exercise Price Per Share Expiration anniversary date of issuance Expiration Anniversary Date Of Issuance Fair value of warrants estimated Warrants Not Settleable In Cash Fair Value Disclosure Expected stock price volatility (as a percent) Fair Value Assumptions Expected Volatility Rate Risk-free interest rate (as a percent) Fair Value Assumptions Risk Free Interest Rate Expected life Fair Value Assumptions Expected Term Expected dividend Fair Value Assumptions Expected Dividend Payments Represents the percentage of development costs related to joint development of any products for which the entity is responsible. Represents the aggregate development costs. Represents the period within which the entity terminates the agreement. Represents the amount of fees related to termination of the agreement. Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others By Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research And Development Arrangement Contract To Perform For Others Type [Domain] Phase Ib clinical trials. Phase Ib Clinical Trials Phase Ib Clinical Trials [Member] Phase II clinical trials. Phase II Clinical Trials Phase I I Clinical Trials [Member] Represents information pertaining to the common stock purchase agreement entered into by the entity. Common Stock Purchase Agreement Common Stock Purchase Agreement [Member] Co-development and license agreement Percentage of development costs related to joint development of products Percentage Of Development Costs Related To Joint Development Of Products Share of aggregate development cost following completion of Phase Ib clinical trials and animal toxicology studies Aggregate Development Costs Period within which agreement is terminated related to Phase Ib clinical trials milestone Period Within Which Agreement Is Terminated Termination fee related to Phase Ib clinical trial milestone Fees For Termination Of Agreement Payments for development cost. Payment of development costs Payments For Development Cost Common stock agreed to be issued (in shares) Common Stock Shares Subscribed But Unissued Net proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Issuance of warrant price per warrant share. Equity [Abstract] Disclosure for stockholders equity. Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Line Items] Stockholders Equity [Line Items] Gross proceeds from issuance of common stock and warrants Sale of common stock, price per share Sale Of Stock Price Per Share Warrants price per share Issuance Of Warrant Price Per Warrant Share Initial exercise price of warrants Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 Warrants expiration date Investment Warrants Expiration Date Net proceeds from sale of common stock Sale Of Stock Consideration Received On Transaction Registration rights agreement date. Registration rights agreement term. Registration rights agreement penalty percentage on failure to meet effectiveness deadline. Registration rights agreement date Registration Rights Agreement Date Registration rights agreement term Registration Rights Agreement Term Penalty percentage for not meeting the registration agreement Registration Rights Agreement Penalty Percentage On Failure To Meet Effectiveness Deadline Risk-free interest rate (as a percent) Expected life Expected dividend rate (as a percent) Fair Value Assumptions Expected Dividend Rate Share based compensation arrangement by share based payment award percentage of additional shares authorized. Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Twenty thirteen equity incentive plan. 2013 Equity Incentive Plan Twenty Thirteen Equity Incentive Plan [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Stock Option Employee Stock Option [Member] Amended and restated equity incentive plan. Amended And Restated Equity Incentive Plan Amended And Restated Equity Incentive Plan [Member] Stock Option Plan Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Increase in number of shares authorized for issuance Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Shares authorized for issuance under the plan Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Additional shares authorized for issuance under the plan as percentage of total shares outstanding Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Additional Shares Authorized Term of share-based award Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Stock Options Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Outstanding at the beginning of period (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Forfeited (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Outstanding at the end of the period (in shares) Exercisable at the end of the period (in shares) Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Available for future grant (in shares) Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Weighted-Average Exercise Price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Outstanding at the beginning of period (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Forfeited (in dollars per share) Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Outstanding at the end of the period (in dollars per share) Exercisable at the end of the period (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Expected term (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Risk free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Grant date fair value per share of common stock Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Assumptions used in fair value of each stock option to purchase common stock using the Black-Scholes option pricing model Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Fair value of common stock on grant date (in dollars per share) Additional disclosure Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract] Stock based compensation expense Allocated Share Based Compensation Expense Total unrecognized compensation costs related to non-vested awards (in dollars) Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period over which unrecognized compensation costs related to non-vested awards is expected to be recognized Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 Weighted average contractual term of the options outstanding Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Intrinsic value of outstanding stock options (in dollars) Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Dividend yield (as a percent) Area of office space Area Of Land Estimated annual rent payable Operating Leases Rent Expense Minimum Rentals Lease term Lessee Leasing Arrangements Operating Leases Term Of Contract Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Investor Investor [Member] Certain stockholders Beneficial Owner [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Related party expenses Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party Extension of milestone payment. Potential extension payment. Additional annual payment for each extension. Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent event Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Extension of milestone payment Extension Of Milestone Payment Potential extension payment Potential Extension Payment Additional payment for each extension Additional Annual Payment For Each Extension Stock options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Stock options weighted average exercise price Vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1